XBiotech's Vilamakitug Meets Primary Efficacy Goal in Phase II Colorectal Cancer Trial

Bitget2026/10/19 13:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

XBiotech today announced positive final Phase II TASKIN results for vilamakitug in refractory metastatic colorectal cancer, meeting the prespecified primary efficacy criterion.
The trial evaluated vilamakitug added to standard treatment; an exploratory analysis showed a statistically significant survival benefit in patients with right-sided tumors.
The findings support a focus on right-sided disease as vilamakitug advances toward registrational clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XBiotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190900PRIMZONEFULLFEED9848126) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

XBiotech's Vilamakitug Meets Primary Efficacy Goal in Phase II Colorectal Cancer Trial

You may also like

Crypto prices